As part of the series,Breaking down diabetes, physician Randall Stafford provides a straightforward guide to medications that can treat Type 2 diabetes.
Metformin is physician-researcher Randall Stafford's go-to drug for diabetes. He explains why in this installment in the series, Breaking down diabetes.
Technology that sends blood sugar-level updates to their smartphones improves outcomes for young people with type 1 diabetes, a Stanford trial shows.
Stanford University bioengineers are developing a faster-acting formulation of insulin that can help diabetes patients better regulate their blood sugar levels.
A Stanford team is developing a bioscaffold that helps insulin-producing cells get enough oxygen when transplanted for diabetes treatment.
Taking a community-based approach to diabetes could help curb high rates of the disease in less wealthy nations, new research suggests.
The latest type 1 diabetes technology improves the stability of patients' blood sugar levels throughout the day and during sleep, according to a new trial.
A therapy delayed the onset of Type 1 diabetes in at-risk people by about two years, new results from a clinical trial show.
Scientists monitored 106 individuals (some of whom have prediabetes) to see how the condition, and infections, impact immune-and-microbiome-related health.
Results from a multi-center clinical trial show that a drug lowers the risk of kidney failure by a third in people with Type 2 diabetes and kidney disease.
Type 1 diabetes starts out as a sneak attack by bad-actor antibodies. But scientists at Stanford and UCSF have developed an early-warning system.
By delivering a drug directly to beta cells, researchers may be able to spur insulin production and potentially develop a diabetes therapy in the future.
Access and cost of insulin is affecting those who need it most, and without major improvements, millions will be without a treatment, a new study suggests.
Scientists find new potential drug targets for heart disease and diabetes, while shedding more light on the genetics of cholesterol, a new study has found.
Although pioneering scientist Gerald Reaven thought that insulin resistance did not affect the kidney, new research suggests that the story is more complex.
A diabetes program, developed with a Stanford scientist, helps cut costs of diabetes-related health care expenses by $815 per year per person.